Annamycin (also known as naxtarubicin) — Full data
in 2026
The investigator is expected to issue a publication or CSR in 2026 on this study.Source filing
MBRX biotech catalysts & pipeline
MOLECULIN BIOTECH INC · Data as of 2026-09-08
Upcoming catalysts
WP1066 — Full data
H2 2026
A manuscript covering the prior pediatric study for WP1066 treating brain tumors conducted at Emory University has been drafted and was accepted for publication, expected in the second half of 2026.Source filing
Annamycin (also known as naxtarubicin) — Topline data
Dec 2026–Feb 2027
The unblinding of Part A's full 90 subjects (including the first 45 subjects already released) is expected in the December 2026 to February 2027 timeframe, thereby concluding Part A of the two-part trial.Source filing
Annamycin (also known as naxtarubicin) — Topline data
2028
● 2028: Primary efficacy data for MIRACLE 2nd line subjectsSource filing
Annamycin (also known as naxtarubicin) — NDA/BLA submission
2028
● 2028: Begin submission of a Rolling New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLESource filing
Annamycin (also known as naxtarubicin) — NDA/BLA submission
2029
● 2029: NDA submission completeSource filing